- ホーム
- > 洋書
- > 英文書
- > Science / Mathematics
Full Description
Therapeutic Potentials of Tenofovir Alafenamide in Hepatitis B offers a comprehensive examination of the therapeutic potentials of Tenofovir Alafenamide (TAF) in hepatitis B, providing a succinct and up-to-date summary of all relevant evidence for this first-line oral antiviral agent. Readers will discover the diverse potential applications of TAF in chronic hepatitis B, informed by valuable lessons learned from HIV treatment, while gaining insights into future therapeutic possibilities. Authored by leading experts in the field, each chapter presents focused and insightful perspectives, making this book an indispensable resource for practitioners and researchers alike. The text delves into key topics such as the pharmacological profile of TAF, its comparative efficacy against traditional antiviral agents, safety and tolerability, and the impact of TAF on drug resistance. Additionally, it explores the use of TAF in special populations, including pediatrics, the elderly, and individuals with renal impairment, as well as future directions in hepatitis B treatment strategies. Serving as a critical resource for physicians, researchers, pharmacologists, and biomedical scientists, this book highlights the core knowledge necessary for understanding TAF and its clinical applications. It identifies key areas for further research and encourages collaborative studies among recognized leaders in the field, ultimately advancing the understanding and treatment of hepatitis B.
Contents
1. Introduction to Hepatitis B and Current Therapeutic Strategies
2. Pharmacological Profile of Tenofovir Alafenamide and mechanisms of action of TAF
3. Comparative Efficacy of TAF Versus Traditional Antiviral Agents: Data from Clinical Trials and Real-World Studies
4. Safety and Tolerability of Tenofovir Alafenamide
5. Impact of TAF on Drug Resistance in Hepatitis B
6. Long-Term Effects of TAF on Liver-related Outcomes and Health
7. TAF in Special Populations part 1: Pediatrics, Elderly, Pregnancy, Immunosuppressed populations
8. TAF in Special Populations part 2: Hepatic impairment and co-infections
9. TAF in Special Populations part 3: Renal impairment
10. Future Directions in Hepatitis B Treatment and the Role of TAF
